VACY AS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| - PTS | -.--% |
|
-.--% | -.--% |
| 14/05 | Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024 | |
| 14/05 | Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 21,356 | 23,372 | 8,287 | 6,988 | 4,790 | - | - |
| Enterprise Value (EV) 1 | 21,356 | 21,490 | 6,164 | 5,327 | 3,536 | 3,781 | 4,790 |
| P/E ratio | 17.6 x | -307 x | -18.1 x | -16.8 x | -6.81 x | -7.04 x | -5.24 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 74.5 x | 88.8 x | 49.5 x | 22.4 x | 25 x | 22.1 x |
| EV / Revenue | - | 68.5 x | 66.1 x | 37.8 x | 16.5 x | 19.8 x | 22.1 x |
| EV / EBITDA | - | -244 x | -11.4 x | -8.99 x | -5.3 x | -4.92 x | -4.04 x |
| EV / FCF | - | 8,641 x | -25.5 x | -5.11 x | -5.3 x | -4.47 x | -3.33 x |
| FCF Yield | - | 0.01% | -3.92% | -19.6% | -18.9% | -22.4% | -30% |
| Price to Book | - | - | 5.11 x | 3.85 x | 3.71 x | 4.49 x | - |
| Nbr of stocks (in thousands) | 2,84,785 | 2,89,619 | 2,94,694 | 3,26,546 | 3,26,546 | - | - |
| Reference price 2 | 74.99 | 80.70 | 28.12 | 21.40 | 14.73 | 14.73 | 14.73 |
| Announcement Date | 21/04/21 | 31/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 12.45 | - | 313.5 | 93.31 | 141.1 | 214.2 | 191.2 | 216.4 |
| EBITDA 1 | -98.76 | - | -87.93 | -542.7 | -592.6 | -667.6 | -768.6 | -1,186 |
| EBIT 1 | -98.89 | - | -94.36 | -549.3 | -615.1 | -693.5 | -797.2 | -1,224 |
| Operating Margin | -794.57% | - | -30.1% | -588.66% | -435.95% | -323.74% | -416.85% | -565.5% |
| Earnings before Tax (EBT) 1 | -95.96 | - | -97.36 | -526.9 | -466.9 | -722.7 | -778.4 | -1,251 |
| Net income 1 | - | 1,249 | -82.32 | -441.7 | -372.3 | -705.4 | -741.2 | -1,251 |
| Net margin | - | - | -26.26% | -473.34% | -263.86% | -329.29% | -387.57% | -578% |
| EPS 2 | -0.3491 | 4.253 | -0.2627 | -1.550 | -1.271 | -2.164 | -2.091 | -2.813 |
| Free Cash Flow 1 | - | - | 2.487 | -241.5 | -1,043 | -667.6 | -845.6 | -1,439 |
| FCF margin | - | - | 0.79% | -258.79% | -739.52% | -311.62% | -442.19% | -665% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 15/04/20 | 21/04/21 | 31/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 278.3 | 33.2 | 13.02 | 34.1 | 33.3 | 54.2 | 30.31 | 24.14 | 10.99 | 68.16 | 68.16 | 68.16 |
| EBITDA 1 | 132.5 | -94.91 | -197.4 | - | - | -121.1 | -148.4 | -175.6 | -162.7 | -164.5 | -168.8 | -173.1 |
| EBIT 1 | 128.8 | -99.37 | -202.1 | -148.6 | - | -126.9 | -154.3 | -181.6 | -168.8 | -170.9 | -175.3 | -179.6 |
| Operating Margin | 46.28% | -299.33% | -1,552.65% | -435.82% | - | -234.1% | -509.11% | -752.19% | -1,535.83% | -250.79% | -257.14% | -263.49% |
| Earnings before Tax (EBT) 1 | 133.9 | -105.9 | -194.9 | -127.2 | - | -108.7 | -133.9 | -100.2 | -178 | -177.4 | -181.8 | -186.1 |
| Net income 1 | 94.31 | -84.85 | -151.2 | -126.1 | - | -97.9 | -110.5 | -56.53 | -161.7 | -177.4 | -181.8 | -186.1 |
| Net margin | 33.89% | -255.59% | -1,161.39% | -369.88% | - | -180.61% | -364.43% | -234.12% | -1,470.87% | -260.32% | -266.67% | -273.02% |
| EPS 2 | - | - | - | -0.4134 | - | -0.3188 | -0.3235 | -0.2118 | -0.5410 | -0.5410 | -0.5410 | -0.5410 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 31/03/22 | 23/08/22 | 23/11/22 | 28/02/23 | 12/05/23 | 22/08/23 | 15/11/23 | 28/02/24 | 14/05/24 | - | - | - |
1NOK in Million2NOK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 1,882 | 2,123 | 1,661 | 1,255 | 1,009 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 2.49 | -241 | -1,043 | -668 | -846 | -1,439 |
| ROE (net income / shareholders' equity) | - | - | -5.05% | -24.3% | -21.4% | -32.9% | -66.1% | - |
| ROA (Net income/ Total Assets) | - | - | -3.8% | -17.6% | - | -25.8% | -30.3% | - |
| Assets 1 | - | - | 2,167 | 2,516 | - | 2,734 | 2,446 | - |
| Book Value Per Share 2 | - | - | - | 5.510 | 5.550 | 3.970 | 3.280 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | - | - | 27.6 | 20.1 | 16.2 | 14.5 | 43.3 |
| Capex / Sales | - | - | - | 29.62% | 14.28% | 7.58% | 7.6% | 20% |
| Announcement Date | 15/04/20 | 21/04/21 | 31/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
14.73
NOK
Average target price
43
NOK
Spread / Average Target
+191.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.90% | 113B | |
| +10.34% | 106B | |
| +0.41% | 22.27B | |
| -11.88% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -5.92% | 17.24B | |
| +7.05% | 14.29B | |
| +36.43% | 12.52B |
- Stock Market
- Equities
- VACC Stock
- VACC Stock
- Financials VACY AS
